Ly3090106    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
53Sjogren syndrome2

53. Sjogren syndrome    [ 234 clinical trials,   270 drugs,   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways]
Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04563195
(ClinicalTrials.gov)
November 202012/9/2020BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromeBAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's SyndromePrimary Sjogren's SyndromeDrug: tibulizumab (LY3090106)Matthew C. BakerNULLNot yet recruiting18 Years85 YearsAll12Phase 2;Phase 3United States
2NCT02614716
(ClinicalTrials.gov)
December 10, 201524/11/2015A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's SyndromeSjögren's SyndromeDrug: LY3090106;Drug: PlaceboEli Lilly and CompanyNULLCompleted18 Years65 YearsAll32Phase 1United States;Bulgaria;Georgia;Romania